Seer launched the Proteograph ONE workflow and SP200 automation instrument in June, marking a major inflection point for large-scale proteomics research.
The new workflow more than doubled throughput to over 1,000 samples per week, with a 30% reduction in run time to approximately 4.5 hours, enabling high-volume studies.
Feedback from key opinion leaders (KOLs) has been highly positive, with early data presentations at industry conferences demonstrating the technology's potential for large population studies.
Proteograph ONE allows identification of up to 10x more proteins than traditional workflows, with improved precision and potential cost reductions per sample.
The launch has already facilitated large-scale population studies, including a 20,000 sample study with Korea University and a 10,000 sample study with Discovery Life Sciences.
Seres has advanced preparation for the next stage of SER-155 development, including a Phase II protocol submission to the FDA.
The Phase Ib study showed a 77% relative risk reduction in bloodstream infections in allo-HSCT patients, supporting further development.
The upcoming Phase II study is designed to enroll approximately 248 patients with an adaptive design and interim analysis, with results expected within 12 months of initiation.
Positive interactions with the FDA and breakthrough therapy designation facilitate the study design and potential approval pathway.
The company aims to use interim data to inform next steps, including potential engagement with the FDA for a registrational study.
Advancement of HiFi Sequencing and Its Impact on Genomic Research
PacBio's HiFi sequencing technology enables reading native single DNA molecules up to 25 kb with high accuracy, including epigenetic modifications, at scale.
The launch of SPRQ chemistry has increased throughput by 33%, lowered cost per genome, and reduced DNA input requirements four-fold, contributing to a record 66% year-over-year increase in sequencing gigabase output.
The technology is foundational for large-scale population genomics, exemplified by the first Arab human pangenome published in Nature Communications, uncovering millions of previously undetected variants.
Management emphasizes that HiFi is gaining significant adoption in research, clinical, and population genomics markets, positioning PacBio as a leader in sequencing accuracy.
Strategic Focus on Phase III Readouts and Clinical Progress
The company is actively progressing towards multiple pivotal Phase III trials, including in myelofibrosis and endometrial cancer, with top-line data expected in 2026.
There is a strong emphasis on the potential of selinexor in combination with ruxolitinib to redefine the standard of care for myelofibrosis, with an estimated peak revenue potential of up to $1 billion annually in the U.S.
Management highlighted the significance of recent enrollment milestones, such as closing new patient screening for the SENTRY trial in myelofibrosis, which is a key step in their clinical development strategy.
The company is leveraging its clinical data to support regulatory and commercial ambitions, emphasizing the potential for selinexor to address unmet needs in diseases with limited treatment options.
Progress and Strategic Opportunities for SGR-1505 MALT1 Inhibitor
Initial Phase I data for SGR-1505 showed a well-tolerated profile with responses in heavily pretreated CLL and Waldenstrom's macroglobulinemia patients, with 3 of 17 CLL patients responding and all 5 Waldenstrom's patients responding.
The program has received FDA Fast Track designation, highlighting its potential as a promising therapeutic in refractory hematologic cancers.
Schrodinger is exploring strategic opportunities to accelerate clinical development and maximize the potential of SGR-1505, rather than pursuing independent late-stage trials.
The company plans to provide further updates on dose escalation, translational data, and regulatory feedback later this year.
The emerging profile of SGR-1505 suggests best-in-class potential, with early evidence supporting its use in refractory disease, especially in patients previously exposed to BTK and BCL2 inhibitors.
Open-Sourcing Boltz-2 to Accelerate Protein Structure Modeling
Recursion open-sourced the Boltz-2 project, which has nearly 200,000 downloads and 50,000 unique users.
The decision to open source was driven by a strategic choice to commoditize certain tools and foster broader industry progress.
Boltz-2 achieves near physics-based accuracy in binding predictions with 1,000-fold less compute, significantly advancing the field of protein folding and ligand binding predictions.
Strategic Investment in Multi-Omics and Proteomics Expansion
Illumina's acquisition of SomaLogic from Standard BioTools for $350 million, expected to close in the first half of 2026, aims to expand the company's presence in affinity-based proteomics.
SomaLogic's SomaScan Assay analyzes over 9,500 human proteins, providing deep insights for drug discovery, diagnostics, and health monitoring, with proprietary SOMAmer reagents offering unmatched sensitivity and scalability.
Integration of SomaLogic's technology is expected to accelerate innovation, scale customer adoption, and enhance operational efficiencies, supporting a comprehensive multi-omic portfolio including DNA, RNA, methylation, and proteomics.
The strategic move aims to embed proteomics more deeply into Illumina's ecosystem, potentially extending SomaLogic's technology into single cell and spatial multi-omic applications.
Adjusted diluted net earnings per share were $1.80, up approximately 5% year-over-year.
Adjusted operating profit margin was 27.3%, flat year-over-year, driven by volume leverage, product mix, and cost management.
Biotechnology segment core revenue increased 6%, led by high single-digit growth in bioprocessing and a slight decline in discovery and medical.
Cepheid's non-respiratory molecular diagnostics grew double digits, driven by sexual health, virology, and hospital-acquired infections assays.
Diagnostics segment core revenue increased 2%, with strong growth outside China, especially in clinical diagnostics and molecular diagnostics non-respiratory revenue.
Free cash flow was $1.1 billion in the quarter and $2.2 billion in the first half, with a 143% free cash flow to net income conversion ratio year-to-date.
Life sciences segment core revenue declined 2.5%, impacted by weak academic and government demand and lower genomics consumables sales.
Second quarter sales were $5.9 billion with 1.5% core revenue growth year-over-year.
Dafinchi
